Mansour Almnajam, MD
Cardiovascular Disease · Muncie, INNPI 1265815229
Payments from drug & device makers
What this record shows
The money is spread across several categories — grants (45.7%), travel and lodging and food and beverage — rather than concentrated in one kind of arrangement. 25 manufacturers reported payments, led by Boston Scientific at 46.8% of the total. Among cardiovascular disease clinicians in IN with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 402 payments — averaging $171.57 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Boston Scientific$32K
- Abbott$14K
- Medtronic$11K
- Biotronik Inc.$8K
- Baylis Medical Company Inc$695
- Cardiva Medical, Inc.$461
- plus $2K from 19 others
What the payments were for
- Grants$31,50046%
- Travel & lodging$20,06929%
- Food & beverage$16,36324%
- Education$1,0382%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Boston Scientific | 28 | $32,308 |
| Abbott | 131 | $14,239 |
| Medtronic | 92 | $11,179 |
| Biotronik Inc. | 69 | $8,128 |
| Baylis Medical Company Inc | 4 | $695 |
| Cardiva Medical, Inc. | 10 | $461 |
| Biosense Webster, Inc. | 16 | $391 |
| Medical Device Business Services, Inc. | 9 | $296 |
| Philips North America LLC | 3 | $255 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 3 | $252 |
| Pfizer | 11 | $174 |
| AstraZeneca | 5 | $143 |
| Penumbra, Inc. | 5 | $107 |
| Teleflex LLC | 2 | $59 |
| E.r. Squibb & Sons, L.L.C. | 3 | $57 |
| Novartis | 2 | $47 |
| Edwards Lifesciences | 1 | $36 |
| Irhythm Technologies, Inc. | 1 | $27 |
| Boehringer Ingelheim | 1 | $23 |
| Lantheus Medical Imaging, Inc. | 1 | $18 |
| Cordis US CORP. | 1 | $17 |
| Johnson & Johnson | 1 | $15 |
| Cvrx, Inc. | 1 | $15 |
| Heartflow, Inc. | 1 | $14 |
| Chiesi USA, Inc. | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- EMBLEM MRI S-ICD$15,361
- EMBLEM S ICD ELECTRODE DELIVERY SYSTEM$15,000
- ENSITE$4,765
- ENSITE PRECISION$2,256
- Micra$2,207
- Ensite Cardiac Mapping System$1,452
- Arctic Front$1,078
- AVEIR$1,005
- Acticor 7 VR-T DX$690
- VersaCross Access Solution$640
- AMVIA EDGE$545
- QUADRA ASSURA$402
- CardioMEMS HF System$343
- Selectra$319
- Solia$319
- Quadra Assura CRT Defibrillator$297
- Carto 3$275
- JOT DX$265
- Cardiva VASCADE MVP VVCS 6-12F$251
- WATCHMAN Access System$221
How this compares
$68,970 in reported general payments places this provider in the 90th percentile of 408 cardiovascular disease providers in Indiana.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 278 | $324,323 |
| XareltoRivaroxaban | 31 | $42,158 |
| EntrestoSacubitril/Valsartan | 11 | $15,434 |
| Amiodarone Hcl | 131 | $2,515 |
| Metoprolol Succinate | 149 | $1,514 |
| PaceroneAmiodarone Hcl | 11 | $979 |
| Flecainide Acetate | 19 | $946 |
| SotalolSotalol Hcl | 33 | $890 |
| Pantoprazole Sodium | 49 | $696 |
| Ranolazine ErRanolazine | 14 | $584 |
| Diltiazem 24hr Er (Cd)Diltiazem Hcl | 14 | $327 |
| Amlodipine Besylate | 37 | $282 |
| Warfarin Sodium | 15 | $183 |
| Hydrochlorothiazide | 23 | $163 |
| ClopidogrelClopidogrel Bisulfate | 18 | $149 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $174 | $324,323278 claims |
| Johnson & JohnsonXarelto | $15 | $42,15831 claims |
| NovartisEntresto | $47 | $15,43411 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 408 cardiovascular disease providers in Indiana.
Other cardiovascular disease in Muncie
- Antonio Navarrete-CasasMuncie$39K
- John MillerIndianapolis$354K
- David KovacichIndianapolis$327K
- Wai LeeElkhart$321K
- Anas SafadiHobart$295K
- Lawrence RinkBloomington$280K
- Vijay RaoIndianapolis$247K
- Steven SteinhublLafayette$247K
- Atul ChughIndianapolis$242K
- James TrippiIndianapolis$239K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.